Can antiviral therapy of chronic hepatitis B prevent the development of hepatocellular carcinoma?

Gut

Volumn 60, Issue 8, 2011, Pages 1025-1026

  Thursz, Mark ^a   Brown, Ashley ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PLACEBO; VIRUS DNA;

CANCER PREVENTION; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK REDUCTION; SEROCONVERSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS LOAD;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE;

EID: 79960303427     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.236521     Document Type: Note

References (16)

1. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55.
2. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20. (Pubitemid 43357805)
3. Chang TT, Gish RG, deMan R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10. (Pubitemid 43357804)
4. Heathcote E, Gane EJ, deMan RA, et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary Analysis [abstract]. Hepatology 2010;52(Suppl):556A.
5. Lampertico P, Vigano M, Soffredini R, et al. Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: the Italian multicenter experience [abstract]. Hepatology 2010;52(Suppl):514A.
6. 10 copies/mL): preliminary analysis [abstract]. Hepatology 2010;52(Suppl):388A.
7. Hadziyannis SJ, Sevastianos V, Rapti IN, et al. Sustained biochemical and virological remission after discontiuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B [abstract]. Hepatology 2006;44(Suppl):231A.
8. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886-93.
9. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transpl 2008;14(Suppl 2):S1-7.
10. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
11. Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis on oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011;60:1109-16.
12. Fattovich G, Brollo L, Boscaro S, et al. Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol 1989;9:331-7. (Pubitemid 19264997)
13. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol 2010;53:348-56.
14. Wong GL, Yiu KK, Wong VW, et al. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 2010;32:1059-68.
15. Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on longterm lamivudine therapy. Antivir Ther 2005;10:431-9. (Pubitemid 41151021)
16. Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004;11:439-42. (Pubitemid 39336225)